Archives
-
Oridonin, Inflammation, and Esophageal Cancer
2026-09-30
Peng et al. investigate whether oridonin suppresses experimental esophageal cancer by attenuating the TLR4/NF-κB/NLRP3 inflammatory axis. Their mouse study links improved tissue pathology and systemic inflammatory indices with changes in inflammasome-related proteins, proliferation markers, and apoptosis-associated transcripts, while also defining important limits for translation beyond the model.
-
ω-Agatoxin IVA Suppresses Seizures in Rats
2026-09-30
This rat study identifies selective P/Q-type (Cav2.1) calcium-channel blockade as a potential anticonvulsant and neuroprotective strategy. ω-Agatoxin IVA delayed seizure onset, reduced kindling and epileptic discharges, increased BDNF, and decreased cleaved caspase-3 without detectable motor-coordination impairment.
-
Prednisolone Workflows for Glucocorticoid Research
2026-09-29
Build reproducible Prednisolone assays for glucocorticoid receptor signaling, inflammation modulation, and corticosteroid-response profiling. A separate ERAD-focused section shows how the latest targeted degradation work can inform assay design without confusing receptor activation with transmembrane protein degradation.
-
GSK 2837808A: From LDHA to Tumor Immunity
2026-09-29
GSK 2837808A offers a focused way to interrogate LDHA-dependent lactate production while extending cancer metabolism research toward immune regulation. This article connects established hepatocellular carcinoma evidence with the NAT1–ENO1–lactate–PD-L1 mechanism reported in colorectal cancer, while clearly separating validated findings from hypothesis-generating translational strategies.
-
Lactate as a Causal Signal in Metabolic Research
2026-09-28
Lactate is both a glycolytic readout and an active regulator of redox, mitochondrial, hypoxia, and immune biology. This article develops a causal assay framework based on the NAT1–ENO1–lactate–TRAF6–PD-L1 pathway and explains how to distinguish metabolic association from mechanism.
-
Lovastatin Workflows for Mevalonate Research
2026-09-28
Use Lovastatin to probe HMG-CoA reductase activity across cholesterol metabolism, proliferation, apoptosis, and macrophage efferocytosis. This guide pairs model-specific dose planning with practical controls, while using a plant meristem study as a lesson in time-resolved experimental design—not as evidence of a direct plant–drug connection.
-
FGFR Inhibition Beyond Oncology: Lessons from NVP-BGJ398
2026-09-27
NVP-BGJ398 phosphate offers a way to test how FGFR1–3 signaling shapes biomarker-defined cancer models—and, with appropriate boundaries, to learn from emerging FGFR3 research in skeletal disease. This article connects target engagement to experimental design, translational interpretation, and the limits of cross-domain inference.
-
SU 5402 as a Pathway Probe in Human Neurons
2026-09-26
SU 5402 is a multi-target receptor tyrosine kinase inhibitor with established applications in cancer biology. This article examines how to use it cautiously as a pathway perturbation in human sensory-neuron studies, building on a human iPSC model of HSV-1 latency without implying that the compound was tested in that study.
-
KNUCKLES Coordinates Hormones to End Floral Meristems
2026-09-25
The study identifies KNUCKLES (KNU) as a regulator of floral meristem termination that links auxin distribution and cytokinin activity to chromatin-based repression of PIN1 and IPT7. Its findings extend the established KNU–WUS pathway and suggest that meristem determinacy depends on coordinating hormone patterns as well as stem-cell gene expression.
-
IDH2, α-KG, and HIF-1α in Colorectal Cancer
2026-09-25
This study links elevated IDH2 with reductive citrate-cycle metabolism, HIF-1α signaling, and colorectal cancer progression. By combining IDH2 inhibition with metabolic and tumor readouts, it identifies a metabolic dependency that may help guide mechanistic studies, while leaving the precise contribution of α-ketoglutarate to HIF regulation open for further testing.
-
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-24
A high-throughput screen identified dasatinib as a candidate for combination with LRPPRC inhibition, revealing complementary suppression of nuclear- and mitochondrial-genome-encoded OXPHOS genes. The findings provide a mechanistic rationale for testing this dual-genome strategy in OXPHOS-dependent cancers, while leaving clinical efficacy and safety to be established.
-
FLCN Variants and mRNA Rescue in Birt-Hogg-Dubé
2026-09-24
A study of two Chinese families links FLCN variants p.W376R and p.Q44* to Birt-Hogg-Dubé syndrome and reports that synthetic FLCN mRNA restored protein expression and corrected mTORC1 dysregulation in cultured cells. The findings add genetic and functional evidence for variant interpretation while positioning mRNA supplementation as an early, in vitro research direction—not an established treatment.
-
Protease Inhibitor Cocktail for OXPHOS Assays
2026-09-23
A Protease Inhibitor Cocktail can help preserve protein integrity in OXPHOS research, but it cannot substitute for careful assay design. Learn how an EDTA-Free Protease Inhibitor supports interpretable protein measurements alongside studies of dual-genome metabolic disruption.
-
Amikacin disulfate: Research Workflows
2026-09-23
Build mechanism-first experiments that connect 16S rRNA targeting, bacterial protein synthesis suppression, and antibiotic resistance research with orthogonal protein-binding assays. This guide translates recent lysozyme-complexation findings into practical, water-based workflows and troubleshooting decisions for reproducible bench studies.
-
NVP-BGJ398 Phosphate: From Signal to Phenotype
2026-09-22
NVP-BGJ398 phosphate is a selective FGFR1–3 inhibitor that connects genotype-defined cancer models with FGFR3-dependent skeletal research. This article explains how to convert pathway suppression into rigorous, phenotype-level evidence using orthogonal assays.